Article in eLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Javier Rangel-MorenoDivision of Allergy, Immunology and Rheumatology, Department of Medicine, University of Rochester Medical Center, Rochester, United States.ORCID https://orcid.org/0000-0002-9738-1182
Yun TaoDepartment of Microbiology, The University of Chicago, Chicago, United States.
Mushtaq AhmedDepartment of Microbiology, The University of Chicago, Chicago, United States.
Kuldeep Singh ChauhanDepartment of Microbiology, The University of Chicago, Chicago, United States.
Daniela Trejo-Ponce de LeonTechnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico.
Gustavo Ramírez-MartínezLaboratory of Immunobiology and Genetics and Department of Pathology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City, Mexico.ORCID https://orcid.org/0000-0001-5157-0677
Luis Jiménez-AlvarezLaboratory of Immunobiology and Genetics and Department of Pathology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City, Mexico.ORCID https://orcid.org/0000-0002-5326-2720
Cesar Luna-RiveroLaboratory of Immunobiology and Genetics and Department of Pathology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City, Mexico.
The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
ROLE OF INDUCIBLE BRONCHUS ASSOCIATED LYMPHOID TISSUE IN LATENT TUBERCULOSISR01AI111914 · NIAID · WASHINGTON UNIVERSITY · PI KAUSHAL, DEEPAK, KHADER, SHABAANA A. · 2015 to 2025
$11.1M
ROLE OF IL-17 IN PROTECTIVE VACCINE-INDUCED IMMUNE RESPONSES AGAINST TUBERCULOSISR01HL105427 · NHLBI · WASHINGTON UNIVERSITY · PI KHADER, SHABAANA A. · 2011 to 2025
$5.9M
The Role of Group 3 Innate Lymphoid cells (ILC3) in TuberculosisR01AI134236 · NIAID · WASHINGTON UNIVERSITY · PI COLONNA, MARCO, KHADER, SHABAANA A. · 2017 to 2021
$4.4M
COMMON IMMUNE CORRELATES OF RISK OF TB DISEASE IN ANIMAL MODELS AND HUMANSR01AI123780 · NIAID · WASHINGTON UNIVERSITY · PI KAUSHAL, DEEPAK, KHADER, SHABAANA A. · 2016 to 2019
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mast cells promote pathology and susceptibility in tuberculosis. · full record | OpenQuestion